Skip to main content
Erschienen in: Pathology & Oncology Research 2/2019

31.10.2018 | Original Article

Sarcomas of the Oral and Maxillofacial Region: Analysis of 26 Cases with Emphasis on Diagnostic Challenges

verfasst von: Priya Kumar, Varun Surya, Aadithya B. Urs, J. Augustine, Sujata Mohanty, Sunita Gupta

Erschienen in: Pathology & Oncology Research | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Sarcomas of the Oral and Maxillofacial Region (SOMR) are rare lesions which pose diagnostic and management challenges. We analyzed 26 cases of SOMR with respect to clinical presentation, histopathological subtype, treatment modalities, recurrence, and treatment outcome. In our series, Osteosarcoma (OS) was the most common type of sarcoma (7 cases), followed by 5 cases of Ewing’s Sarcoma (ES), 3 cases each of Chondrosarcoma (CS) and Leiomyosarcoma (LMS), 2 cases each of Malignant Peripheral Nerve Sheath Tumor (MPNST), Pleomorphic Undifferentiated Sarcoma (PUS), Myeloid Sarcoma (MS)and Rhabdomyosarcoma (RMS). Surgery was the primary treatment modality in most cases and was combined with adjuvant chemo/ radiotherapy in few cases. 24 of the 26 cases were followed up for an average period of 40.67 months. Adverse disease outcomes like recurrence were seen in 2 cases whereas death due to the disease was reported in 7 cases. In view of the diagnostic challenges faced in SOMRs, it appears practical to stress on the underlying genetic aspects of the disease process rather than histological subtyping to improve disease outcome.
Literatur
1.
Zurück zum Zitat Kraus DH Sarcomas of the head and neck. Curr Oncol Rep 4:68–75 Kraus DH Sarcomas of the head and neck. Curr Oncol Rep 4:68–75
2.
Zurück zum Zitat Greene F, Page D, Fleming I, Fritz A, Balch C, Haller D et al (eds) (2002) American joint committee on Cancer: AJCC Cancer staging manual, 6th edn. Springer, New York, pp 77–87 Greene F, Page D, Fleming I, Fritz A, Balch C, Haller D et al (eds) (2002) American joint committee on Cancer: AJCC Cancer staging manual, 6th edn. Springer, New York, pp 77–87
3.
Zurück zum Zitat Shellenberger T et al (2009) Sarcomas of the head and neck region. Curr Oncol Rep 11:135–142CrossRefPubMed Shellenberger T et al (2009) Sarcomas of the head and neck region. Curr Oncol Rep 11:135–142CrossRefPubMed
4.
Zurück zum Zitat Tran LM, Mark R, Meier R, Calcaterra TC, Parker RG (1992) Sarcomas of the head and neck . Prognostic factors and treatment strategies. Cancer 70:169–177CrossRefPubMed Tran LM, Mark R, Meier R, Calcaterra TC, Parker RG (1992) Sarcomas of the head and neck . Prognostic factors and treatment strategies. Cancer 70:169–177CrossRefPubMed
5.
Zurück zum Zitat O'Neill JP, Bilsky MH, Kraus D (2013) Head and neck sarcomas: epidemiology, pathology, and management. Neurosurg Clin N Am 24(1):67–78CrossRefPubMed O'Neill JP, Bilsky MH, Kraus D (2013) Head and neck sarcomas: epidemiology, pathology, and management. Neurosurg Clin N Am 24(1):67–78CrossRefPubMed
6.
Zurück zum Zitat Stavrakas M, Nixon I, Andi K, Oakley R, Jeannon JP, Lyons A, McGurk M, Urbano TG, Thavaraj S, Simo R (2016) Head and neck sarcomas: clinical and histopathological presentation, treatment modalities, and outcomes. J Laryngol Otol 130(9):850–859CrossRefPubMed Stavrakas M, Nixon I, Andi K, Oakley R, Jeannon JP, Lyons A, McGurk M, Urbano TG, Thavaraj S, Simo R (2016) Head and neck sarcomas: clinical and histopathological presentation, treatment modalities, and outcomes. J Laryngol Otol 130(9):850–859CrossRefPubMed
7.
9.
Zurück zum Zitat Wanebo HJ, Koness RJ, Macfarlane JK, Eilber FR, Byers RM, Elias EG et al (1992) Head and neck sarcoma: report of the head and neck sarcoma registry. Head Neck 14:1–7CrossRefPubMed Wanebo HJ, Koness RJ, Macfarlane JK, Eilber FR, Byers RM, Elias EG et al (1992) Head and neck sarcoma: report of the head and neck sarcoma registry. Head Neck 14:1–7CrossRefPubMed
10.
Zurück zum Zitat Aljabab A, Nason R, Kazi R, Pathak K (2011) Head and neck soft tissue sarcoma. Indian J Surg Oncol 2:286–290CrossRefPubMed Aljabab A, Nason R, Kazi R, Pathak K (2011) Head and neck soft tissue sarcoma. Indian J Surg Oncol 2:286–290CrossRefPubMed
13.
Zurück zum Zitat Hong HR, Jin S, Koo HJ, Roh JL, Kim JS, Cho KJ, Choi SH, Nam SY, Kim SY (2014) Clinical values of (18) F-FDG PET/CT in oral cavity cancer with dental artifacts on CT or MRI. J Surg Oncol 110(6):696–701CrossRefPubMed Hong HR, Jin S, Koo HJ, Roh JL, Kim JS, Cho KJ, Choi SH, Nam SY, Kim SY (2014) Clinical values of (18) F-FDG PET/CT in oral cavity cancer with dental artifacts on CT or MRI. J Surg Oncol 110(6):696–701CrossRefPubMed
14.
Zurück zum Zitat Kumar R, Chauhan A, Vellimana AK, Chawla M (2006) Role of PET/PET-CT in the management of sarcomas. Expert Rev Anticancer Ther 6(8):1241–1250CrossRefPubMed Kumar R, Chauhan A, Vellimana AK, Chawla M (2006) Role of PET/PET-CT in the management of sarcomas. Expert Rev Anticancer Ther 6(8):1241–1250CrossRefPubMed
15.
Zurück zum Zitat Wu JS, Hochman MG (2009) Soft-tissue tumors and tumorlike lesions: a systematic imaging approach. Radiology 253(2):297–316CrossRefPubMed Wu JS, Hochman MG (2009) Soft-tissue tumors and tumorlike lesions: a systematic imaging approach. Radiology 253(2):297–316CrossRefPubMed
16.
Zurück zum Zitat Rekhi B, Gorad BD, Kakade AC, Chinoy R (2007) Scope of FNAC in the diagnosis of soft tissue tumors: a study from a tertiary cancer referral Centre in India. Cytojournal 31:4–20 Rekhi B, Gorad BD, Kakade AC, Chinoy R (2007) Scope of FNAC in the diagnosis of soft tissue tumors: a study from a tertiary cancer referral Centre in India. Cytojournal 31:4–20
17.
Zurück zum Zitat Yoshida A, Ushiku T, Motoi T, Beppu Y, Fukayama M, Tsuda H, Shibata T (2012) MDM2 and CDK4 immunohistochemical coexpression in high-grade osteosarcoma: correlation with a dedifferentiated subtype. Am J Surg Pathol 36(3):423–431CrossRefPubMed Yoshida A, Ushiku T, Motoi T, Beppu Y, Fukayama M, Tsuda H, Shibata T (2012) MDM2 and CDK4 immunohistochemical coexpression in high-grade osteosarcoma: correlation with a dedifferentiated subtype. Am J Surg Pathol 36(3):423–431CrossRefPubMed
18.
Zurück zum Zitat Tabareau-Delalande F, Collin C, Gomez-Brouchet A, Bouvier C, Decouvelaere AV, de Muret A, Pagès JC, de Pinieux G (2014) Chromosome 12 long arm rearrangement covering MDM2 and RASAL1 is associated with aggressive craniofacial juvenile ossifying fibroma and extracranial psammomatoid fibro-osseous lesions. Mod Pathol 28(1):48–56CrossRefPubMed Tabareau-Delalande F, Collin C, Gomez-Brouchet A, Bouvier C, Decouvelaere AV, de Muret A, Pagès JC, de Pinieux G (2014) Chromosome 12 long arm rearrangement covering MDM2 and RASAL1 is associated with aggressive craniofacial juvenile ossifying fibroma and extracranial psammomatoid fibro-osseous lesions. Mod Pathol 28(1):48–56CrossRefPubMed
19.
Zurück zum Zitat Argon A, Doğanavşargıl B, ÜnalYıldırım F, Sezak M, Midilli R, Öztop F (2015) Osteosarcomas of jaw: experience of a single Centre. J Plast Surg Hand Surg 49(1):13–18CrossRefPubMed Argon A, Doğanavşargıl B, ÜnalYıldırım F, Sezak M, Midilli R, Öztop F (2015) Osteosarcomas of jaw: experience of a single Centre. J Plast Surg Hand Surg 49(1):13–18CrossRefPubMed
20.
Zurück zum Zitat Yildiz FR, Avci A, Dereci O, Erol B, Celasun B, Gunhan O (2014) Gnathic osteosarcomas, experience of four institutions from Turkey. Int J Clin Exp Pathol 7(6):2800–2808PubMedPubMedCentral Yildiz FR, Avci A, Dereci O, Erol B, Celasun B, Gunhan O (2014) Gnathic osteosarcomas, experience of four institutions from Turkey. Int J Clin Exp Pathol 7(6):2800–2808PubMedPubMedCentral
21.
Zurück zum Zitat Paparella ML, Olvi LG, Brandizzi D, Keszler A, Santini-Araujo E, Cabrini RL (2013) Osteosarcoma of the jaw: an analysis of a series of 74 cases. Histopathology 63(4):551–557PubMed Paparella ML, Olvi LG, Brandizzi D, Keszler A, Santini-Araujo E, Cabrini RL (2013) Osteosarcoma of the jaw: an analysis of a series of 74 cases. Histopathology 63(4):551–557PubMed
22.
Zurück zum Zitat Gomez-Brouchet A, Mourcin F, Gourraud PA, Bouvier C, De Pinieux G, Le Guelec S, Brousset P, Delisle MB, Schiff C (2010) Galectin-1 is a powerful marker to distinguish chondroblastic osteosarcoma and conventional chondrosarcoma. Hum Pathol 41(9):1220–1230CrossRefPubMed Gomez-Brouchet A, Mourcin F, Gourraud PA, Bouvier C, De Pinieux G, Le Guelec S, Brousset P, Delisle MB, Schiff C (2010) Galectin-1 is a powerful marker to distinguish chondroblastic osteosarcoma and conventional chondrosarcoma. Hum Pathol 41(9):1220–1230CrossRefPubMed
24.
Zurück zum Zitat Lee RJ, Arshi A, Schwartz HC, Christensen RE (2015) Characteristics and prognostic factors of osteosarcoma of the jaws: a retrospective cohort study. JAMA Otolaryngol Head Neck Surg 141(5):470–477CrossRefPubMed Lee RJ, Arshi A, Schwartz HC, Christensen RE (2015) Characteristics and prognostic factors of osteosarcoma of the jaws: a retrospective cohort study. JAMA Otolaryngol Head Neck Surg 141(5):470–477CrossRefPubMed
25.
26.
Zurück zum Zitat Urs AB, Kumar P, Rawat G, Mohanty S (2016) Ewing’s sarcoma of the jaws: an institutional study of four cases. Int J Pediatr Otorhinolaryngol Extra 13:33–39CrossRef Urs AB, Kumar P, Rawat G, Mohanty S (2016) Ewing’s sarcoma of the jaws: an institutional study of four cases. Int J Pediatr Otorhinolaryngol Extra 13:33–39CrossRef
27.
Zurück zum Zitat Lucas DR, Bentley G, Dan ME, Tabaczka P, Poulik JM, Mott MP (2001) Ewing sarcoma vs lymphoblastic lymphoma. A comparative immunohistochemical study. Am J Clin Pathol 115(1):11–17CrossRefPubMed Lucas DR, Bentley G, Dan ME, Tabaczka P, Poulik JM, Mott MP (2001) Ewing sarcoma vs lymphoblastic lymphoma. A comparative immunohistochemical study. Am J Clin Pathol 115(1):11–17CrossRefPubMed
29.
Zurück zum Zitat Wehrli BM, Huang W, De Crombrugghe B, Ayala AG, Czerniak B (2003) Sox9, a master regulator of chondrogenesis, distinguishes mesenchymal chondrosarcoma from other small blue round cell tumors. Hum Pathol 34(3):263–269CrossRefPubMed Wehrli BM, Huang W, De Crombrugghe B, Ayala AG, Czerniak B (2003) Sox9, a master regulator of chondrogenesis, distinguishes mesenchymal chondrosarcoma from other small blue round cell tumors. Hum Pathol 34(3):263–269CrossRefPubMed
30.
Zurück zum Zitat McKay KM, Deavers MT, Prieto VG (2012) Chondroid melanoma metastatic to lung and skin showing SOX-9 expression: a potential diagnostic pitfall. Int J Surg Pathol 20:169–172CrossRefPubMed McKay KM, Deavers MT, Prieto VG (2012) Chondroid melanoma metastatic to lung and skin showing SOX-9 expression: a potential diagnostic pitfall. Int J Surg Pathol 20:169–172CrossRefPubMed
31.
Zurück zum Zitat Nakashima Y, Unni KK, Shives TC, Swee RG, Dahlin DC (1986) Mesenchymal chondrosarcoma of bone and soft tissue. A review of 111 cases. Cancer 15;57(12):2444–2453CrossRef Nakashima Y, Unni KK, Shives TC, Swee RG, Dahlin DC (1986) Mesenchymal chondrosarcoma of bone and soft tissue. A review of 111 cases. Cancer 15;57(12):2444–2453CrossRef
32.
Zurück zum Zitat Vencio EF, Reeve CM, Unni KK, Nascimento AG (1998) Mesenchymal chondrosarcoma of the jaw bones: clinicopathologic study of 19 cases. Cancer 15;82(12):2350–2355CrossRef Vencio EF, Reeve CM, Unni KK, Nascimento AG (1998) Mesenchymal chondrosarcoma of the jaw bones: clinicopathologic study of 19 cases. Cancer 15;82(12):2350–2355CrossRef
33.
Zurück zum Zitat Yan B, Li Y, Pan J, Xia H, Li LJ (2010) Primary oral leiomyosarcoma: a retrospective clinical analysis of 20 cases. Oral Dis 16(2):198–203CrossRefPubMed Yan B, Li Y, Pan J, Xia H, Li LJ (2010) Primary oral leiomyosarcoma: a retrospective clinical analysis of 20 cases. Oral Dis 16(2):198–203CrossRefPubMed
34.
Zurück zum Zitat Vilos GA, Rapidis AD, Lagogiannis GD, Apostolidis C (2005) Leiomyosarcomas of the oral tissuses: clinicopathologic analysis of 50 cases. J Oral Maxillofac Surg 63:1461–1477CrossRefPubMed Vilos GA, Rapidis AD, Lagogiannis GD, Apostolidis C (2005) Leiomyosarcomas of the oral tissuses: clinicopathologic analysis of 50 cases. J Oral Maxillofac Surg 63:1461–1477CrossRefPubMed
35.
Zurück zum Zitat Nikitakis NG, Lopes MA, Bailey JS, Blanchaert RH Jr, Ord RA, Sauk JJ (2002) Oral leiomyosarcoma: review of the literature and report of two cases with assessment of the prognostic and diagnostic significance of immunohistochemical and molecular markers. Oral Oncol 38(2):201–208CrossRefPubMed Nikitakis NG, Lopes MA, Bailey JS, Blanchaert RH Jr, Ord RA, Sauk JJ (2002) Oral leiomyosarcoma: review of the literature and report of two cases with assessment of the prognostic and diagnostic significance of immunohistochemical and molecular markers. Oral Oncol 38(2):201–208CrossRefPubMed
37.
Zurück zum Zitat Montgomery E, Fisher C (2001) Myofibroblastic differentiation in malignant fibrous histiocytoma (pleomorphic myofibrosarcoma): a clinicopathological study. Histopathology 38(6):499–509CrossRefPubMed Montgomery E, Fisher C (2001) Myofibroblastic differentiation in malignant fibrous histiocytoma (pleomorphic myofibrosarcoma): a clinicopathological study. Histopathology 38(6):499–509CrossRefPubMed
38.
Zurück zum Zitat Perez EA, Kassira N, Cheung MC, Koniaris LG, Neville HL, Sola JE (2011) Rhabdomyosarcoma in children: a SEER population based study. J Surg Res 170(2):e243–ee51CrossRefPubMed Perez EA, Kassira N, Cheung MC, Koniaris LG, Neville HL, Sola JE (2011) Rhabdomyosarcoma in children: a SEER population based study. J Surg Res 170(2):e243–ee51CrossRefPubMed
39.
Zurück zum Zitat Chen E, Ricciotti R, Futran N, Oda D (2017) Head and neck rhabdomyosarcoma: clinical and pathologic characterization of seven cases. Head Neck Pathol 11(3):321–326CrossRefPubMed Chen E, Ricciotti R, Futran N, Oda D (2017) Head and neck rhabdomyosarcoma: clinical and pathologic characterization of seven cases. Head Neck Pathol 11(3):321–326CrossRefPubMed
40.
Zurück zum Zitat Woodruff JM, Perino G (1994) Non-germ-cell or teratomatous malignant tumors showing additional rhabdomyoblastic differentiation, with emphasis on the malignant triton tumor. Semin Diagn Pathol 11:69–81PubMed Woodruff JM, Perino G (1994) Non-germ-cell or teratomatous malignant tumors showing additional rhabdomyoblastic differentiation, with emphasis on the malignant triton tumor. Semin Diagn Pathol 11:69–81PubMed
41.
Zurück zum Zitat Devesa P, Mitchell TE, Scott I, Moffat D (2006) Malignant peripheral nerve sheath tumors of the head and neck: two cases and a review of the literature. Ear Nose Throat J 85:392–396CrossRef Devesa P, Mitchell TE, Scott I, Moffat D (2006) Malignant peripheral nerve sheath tumors of the head and neck: two cases and a review of the literature. Ear Nose Throat J 85:392–396CrossRef
42.
Zurück zum Zitat Cleven AH, Sannaa GA, Briaire-de Bruijn I, Ingram DR, van de Rijn M, Rubin BP, de Vries MW, Watson KL, Torres KE, Wang WL, van Duinen SG, Hogendoorn PC, Lazar AJ, Bovée JV (2016) Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival. Mod Pathol 29(6):582–590CrossRefPubMedPubMedCentral Cleven AH, Sannaa GA, Briaire-de Bruijn I, Ingram DR, van de Rijn M, Rubin BP, de Vries MW, Watson KL, Torres KE, Wang WL, van Duinen SG, Hogendoorn PC, Lazar AJ, Bovée JV (2016) Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival. Mod Pathol 29(6):582–590CrossRefPubMedPubMedCentral
43.
Zurück zum Zitat Guo A, Liu A, Wei L, Song X (2012) Malignant peripheral nerve sheath tumors: differentiation patterns and Immunohistochemical features - a mini-review and our new findings. J Cancer 3:303–309CrossRefPubMedPubMedCentral Guo A, Liu A, Wei L, Song X (2012) Malignant peripheral nerve sheath tumors: differentiation patterns and Immunohistochemical features - a mini-review and our new findings. J Cancer 3:303–309CrossRefPubMedPubMedCentral
44.
Zurück zum Zitat Kumar P, Singh H, Khurana N, Urs AB, Augustine J, Tomar R (2017) Diagnostic challenges with intraoral myeloid sarcoma: report of two cases & review of world literature. Exp Oncol 39:78–85CrossRefPubMed Kumar P, Singh H, Khurana N, Urs AB, Augustine J, Tomar R (2017) Diagnostic challenges with intraoral myeloid sarcoma: report of two cases & review of world literature. Exp Oncol 39:78–85CrossRefPubMed
45.
Zurück zum Zitat Demicco EG (2013) Sarcoma diagnosis in the age of molecular pathology. Adv Anat Pathol 20(4):264–274CrossRefPubMed Demicco EG (2013) Sarcoma diagnosis in the age of molecular pathology. Adv Anat Pathol 20(4):264–274CrossRefPubMed
46.
Zurück zum Zitat Mariño-Enríquez A, Bovée JVMG (2016) Molecular pathogenesis, diagnostic, prognostic and predictive molecular markers in sarcoma. Surgical pathology clinics 9(3):457–473CrossRefPubMedPubMedCentral Mariño-Enríquez A, Bovée JVMG (2016) Molecular pathogenesis, diagnostic, prognostic and predictive molecular markers in sarcoma. Surgical pathology clinics 9(3):457–473CrossRefPubMedPubMedCentral
47.
Zurück zum Zitat Antonescu CR, Owosho AA, Zhang L, Chen S, Deniz K, Huryn JM, Kao YC, Huang SC, Singer S, Tap W, Schaefer IM, Fletcher CD (2017) Sarcomas with CIC-rearrangements are a distinct pathologic entity with aggressive outcome: a Clinicopathologic and molecular study of 115 cases. Am J Surg Pathol 41(7):941–949CrossRefPubMedPubMedCentral Antonescu CR, Owosho AA, Zhang L, Chen S, Deniz K, Huryn JM, Kao YC, Huang SC, Singer S, Tap W, Schaefer IM, Fletcher CD (2017) Sarcomas with CIC-rearrangements are a distinct pathologic entity with aggressive outcome: a Clinicopathologic and molecular study of 115 cases. Am J Surg Pathol 41(7):941–949CrossRefPubMedPubMedCentral
48.
Zurück zum Zitat Bovee JV, Hogendoorn PC (2010) Molecular pathology of sarcomas: concepts and clinical implications. Virchows Arch 456(2):193–199CrossRefPubMed Bovee JV, Hogendoorn PC (2010) Molecular pathology of sarcomas: concepts and clinical implications. Virchows Arch 456(2):193–199CrossRefPubMed
49.
Zurück zum Zitat Casali PG, Jost L, Sleijfer S, Verweij J, Blay JY (2008) Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 19(Suppl 2):ii89–ii93PubMed Casali PG, Jost L, Sleijfer S, Verweij J, Blay JY (2008) Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 19(Suppl 2):ii89–ii93PubMed
50.
Zurück zum Zitat Jaetli V, Gupta S (2011) Mesenchymal chondrosarcoma of maxilla: a rare case report. Med Oral Patol Oral Cir Bucal 1;16(4):e493–e496CrossRef Jaetli V, Gupta S (2011) Mesenchymal chondrosarcoma of maxilla: a rare case report. Med Oral Patol Oral Cir Bucal 1;16(4):e493–e496CrossRef
51.
Zurück zum Zitat Gupta SR, Saran RK, Sharma P, Urs AB (2015) A rare case of Extraskeletal mesenchymal chondrosarcoma with dedifferentiation arising from the buccal space in a young male. J Maxillofac Oral Surg 14(Suppl 1):293–299CrossRefPubMed Gupta SR, Saran RK, Sharma P, Urs AB (2015) A rare case of Extraskeletal mesenchymal chondrosarcoma with dedifferentiation arising from the buccal space in a young male. J Maxillofac Oral Surg 14(Suppl 1):293–299CrossRefPubMed
Metadaten
Titel
Sarcomas of the Oral and Maxillofacial Region: Analysis of 26 Cases with Emphasis on Diagnostic Challenges
verfasst von
Priya Kumar
Varun Surya
Aadithya B. Urs
J. Augustine
Sujata Mohanty
Sunita Gupta
Publikationsdatum
31.10.2018
Verlag
Springer Netherlands
Erschienen in
Pathology & Oncology Research / Ausgabe 2/2019
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-018-0510-9

Weitere Artikel der Ausgabe 2/2019

Pathology & Oncology Research 2/2019 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.